Latest Asx Disclosures News

Orcoda Limited has clarified the materiality and timing of disclosures related to its ACTA trial and new SaaS contracts, confirming compliance with ASX Listing Rules and explaining the rationale behind its announcements.

Alterity Therapeutics faces ASX scrutiny after mistakenly marking multiple announcements as market sensitive, prompting a review of its disclosure practices. The biotech denies any intent to manipulate its share price despite repeated errors.

Kaiser Reef reports a solid cash boost to $30.7 million driven by strong production from its Henty and A1 gold mines, while clarifying its gold price risk management strategy.

Botanix Pharmaceuticals confirms material sales and prescription growth data, explaining the timing of its ASX disclosures amid share price fluctuations.

Elsight Limited has responded to ASX concerns over a premature media report on its $60 million capital raise, denying any unauthorized disclosures and reaffirming its compliance with continuous disclosure rules.

333D Limited reported a 12% increase in quarterly cash receipts from digital asset management contracts, maintaining steady cash flow despite slight operating cash usage. The company’s annual contract revenue surpassed $970,000, reflecting growing traction in healthcare digital services.

Raptis Group Limited has confirmed that director James Raptis will resign effective 30 September 2025, affirming the company’s compliance with ASX continuous disclosure rules.

Kingsland Minerals has withdrawn its previously implied production target for the Leliyn Graphite Project’s processing plant, citing non-compliance with ASX disclosure rules and advising investors to disregard prior estimates.

Biome Australia Limited has confirmed its record FY25 sales revenue of approximately $18.4 million, marking a 41% increase year-on-year, while affirming full compliance with ASX continuous disclosure rules.

ENRG Elements Limited has confirmed the materiality of recent director resignations and appointments, clarifying timing and compliance with ASX disclosure rules.

Cygnus Metals has clarified that its recent share price and volume spike stemmed from new assay results at its Golden Eye prospect and broader copper sector dynamics, confirming compliance with ASX disclosure rules.

Locate Technologies has secured $1.45 million through a share placement and established a $2 million At-the-Market facility to boost financial flexibility, while unveiling a strategic plan to hold Bitcoin as part of its treasury management.